BPC-157 and TB-500: How Two Peptides Talk to Healing Tissue

BPC-157 and TB-500 are not FDA-approved for any use.

Update, October 30, 2026: HHS published an interim policy (Federal Register, Oct 30, 2026) saying it will not take enforcement action against state-licensed pharmacies and physicians that compound six peptides, including BPC-157 (injected, oral or topical) and TB-500 (injected), under quality and safety conditions, while FDA writes a formal rule. This is not FDA approval and does not establish safety or effectiveness. FDA staff advised in July 2026 against adding these peptides to the compounding list, and HHS may revisit the policy. Blends of BPC-157 and TB-500 are not covered.

Availability depends on current federal rules; we review options at your visit.

BPC-157 stands for "body protection compound." It is a chain of 15 amino acids taken from a protein in human gastric juice, which is part of why it was first studied for the gut lining.

In laboratory and animal models, researchers have tied it to several repair pathways. It increases VEGF signaling, the main switch for growing new capillaries into damaged tissue. It interacts with the nitric oxide system, which helps regulate vessel tone and circulation. It activates the FAK and paxillin pathway, which lets tendon cells attach, spread and multiply. And in tendon cells it increases growth hormone receptors, which may make the tissue more responsive to the body's own repair signals.

A 2025 systematic review of 39 papers found these effects mostly in muscle, tendon, ligament and bone models in animals. Human data is still thin: the one small human report looked at 12 people after knee injections and found 7 reported lasting pain relief.

TB-500 is a short synthetic version of the active region of thymosin beta-4, a protein your own body makes in high amounts at sites of injury. Its key trick is binding actin, the internal scaffolding cells use to change shape and move.

By regulating actin, thymosin beta-4 helps repair cells and new vessel cells crawl into the wound faster, supports new blood vessel formation in the healing area, and helps inflammatory signals settle, which may mean less scar-like repair.

The parent protein, thymosin beta-4, has been tested in small human trials for eye and skin healing. TB-500 itself has been studied mainly in animals.

Think of BPC-157 as building the roads and TB-500 as moving the crews. One supports blood supply and tissue signaling, the other helps cells reach the injury. That is why the two show up together in sports medicine conversations about tendons, ligaments and muscle.

The mechanism story is compelling and the animal data is consistent. What is missing is large, controlled human trials that tell us the right patients, the right timing and the long-term safety.

The regulatory picture is moving (see Where things stand above), so access and better data may follow. Competitive athletes should know both are on the World Anti-Doping Agency's prohibited list.

At the Institute of Function, recovery is built in layers: an accurate diagnosis, image-guided treatment of the injured structure, and a loading program that rebuilds strength and function. Peptides like BPC-157 and TB-500 would sit in the biologic layer, supporting the tissue while rehab does the rebuilding.

Where we start now: platelet-rich plasma (PRP) and cell-based injections placed under ultrasound guidance, prolotherapy for lax or irritated ligaments, and a progressive loading plan matched to your sport or daily life. As regulated peptide options become available, we will add them where the evidence supports it, always after a private physician assessment.

If you already use BPC-157 or TB-500, our Peptide Consultation offers a confidential review of what you take, the evidence, labs and monitoring.